secwatch / observer
8-K filed December 5, 2025, 6:59 PM ET CIK 0001971543
M&A confidence high sentiment neutral materiality 0.90

Mural Oncology plc: M&A transaction — XOMA Royalty subsidiary completes acquisition of Mural Oncology for $2.035 per share

Mural Oncology plc

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Mural Oncology plc: The Memorandum and Articles of Association were amended pursuant to the Transaction Agreement.

Change
charter amendment
Exact text from the filing
Pursuant to the terms of the Transaction Agreement, immediately following the Effective Time, the Memorandum and Articles of Association of the Company were amended in accordance with the resolution approved at the EGM, as set forth on Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Mural Oncology plc underwent a change of control involving XOMA Royalty Corporation and XRA 5 Corp. for $2.035 in cash (closed 2025-12-05).

Action
change of control
Counterparty
XOMA Royalty Corporation and XRA 5 Corp.
Consideration
$2.035 in cash
Closing
2025-12-05
Exact text from the filing
the Scheme became effective (the “Effective Time”). At the Effective Time, Sub acquired all of the outstanding ordinary shares, nominal value $0.01 per share, of the Company (the “Ordinary Shares,” and such acquired Ordinary Shares, collectively, the “Mural Shares”) and each holder of Mural Shares outstanding as of 11:59 p.m. Irish local time on December 4, 2025, the business day prior to the occurrence of the Effective Time, obtained the right to receive $2.035 in cash (the “Scheme Consideration”) in exchange for each Mural Share held.
View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR
accession 0001193125-25-308710
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.